September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
1 citations
,
November 2006 in “Medicina de Familia SEMERGEN” 1 citations
,
January 2026 in “GigaScience” Cell Journey is a tool for better 3D visualization of cell changes over time.
14 citations
,
August 2024 in “JBMR Plus” January 1980 in “Lluc: revista de cultura i d'idees” Agaricus bisporus β-Glucan particles could effectively treat cervical cancer and offer antimicrobial and antioxidant benefits.
Hair feels different when touched and rubs together in various ways.
March 2019 in “Sexual medicine reviews” 148 citations
,
May 2012 in “The American Journal of Human Genetics” Cantú syndrome is caused by mutations in the ABCC9 gene.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
December 2024 in “Drug Discoveries & Therapeutics” Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
April 2017 in “Journal of Investigative Dermatology” A boy with Oculodentodigital syndrome had a unique GJA1 gene mutation causing his symptoms.
December 2025 in “Dermatology The American Medical Journal” JAK inhibitors are effective for long-term management of alopecia areata.
September 2018 in “Hair transplant forum international” The document's content could not be processed for a summary.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
5 citations
,
April 2022 in “Cell Biology International” JAM-A modification speeds up skin wound healing by boosting fibroblast growth.
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
January 2025 in “International Journal of Pharmaceutical Research and Applications” Hibiscus mucilage is an effective gelling agent for diclofenac diethylamine gel.
September 2025 in “International Journal for Research in Applied Science and Engineering Technology” Guava leaf extracts are beneficial for skin, hair, and oral care.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
April 2018 in “Journal of Investigative Dermatology” CENPV, a new partner of CYLD, helps regulate ciliary acetylated tubulin and is overexpressed in certain skin tumors.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
May 2025 in “Frontiers in Bioinformatics” Jamogenin from plants may help hair growth and is a potential alternative to finasteride.
August 2022 in “Precision Clinical Medicine” JAM-A helps hair regrowth in alopecia areata by protecting VCAN in skin cells.
May 2018 in “Dermatologic Surgery” June 2024 in “Institutional Repository of the Federal Technological University of Paraná (RIUT) (Federal University of Technology – Paraná)” Mapu Cosméticos is profitable and viable, focusing on male hair care products.
August 2025 in “International Journal of Research Publication and Reviews” Quasi-drugs in Japan and South Korea are regulated to ensure safety and effectiveness, offering products with mild therapeutic effects.
80 citations
,
June 1997 in “The American Journal of Human Genetics”